Monopar Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -1,574,902 | -1,788 | -1,723 | -1,911 |
EBIT | -1,574 | -3,577 | -3,446 | -3,823 |
Net Income | -1,304,276 | -1,715 | -1,641 | -1,813 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -4,402,388 | -1,676 | -1,655 | -1,545 |
Cash | 6,020 | 6,119 | 7,807 | 7,266 |
Basic Shares | 35,203 | 3,502 | 15,979 | 14,904 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $122 |
Gross Profit | 122 | |||
EBITDA | 429 | -10,515 | -9,079 | -6,631 |
EBIT | -8,402 | -10,536 | -9,127 | -13,140 |
Net Income | -8,402 | -10,494 | -9,079 | -6,222 |
Net Change In Cash | 0 | 0 | 0 | 122 |
Cost of Revenue | 3,523 | |||
Free Cash Flow | -7,858 | -7,228 | -7,317 | -4,662 |
Cash | 7,266 | 8,186 | 20,303 | 16,737 |
Basic Shares | 14,511 | 12,718 | 12,472 | 10,958 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.37 |
2024-06-30 | -$0.50 |
2024-03-31 | -$0.10 |
2023-12-31 | -$0.12 |
